Daiichi Sankyo presents new analyses from MILOS study of bempedoic acid alone or combined with ezetimibe for dyslipidaemia at ESC Congress (¥2931.0000, 0)
Daiichi Sankyo doses first patient in first-in-human phase 1 trial of DS1025 for advanced or metastatic solid tumors (¥2886.5000, 0)
First patient has been dosed in Daiichi Sankyo and AstraZeneca's TROPION-Urothelial04 phase 3 trial for Datroway plus rilvegostomig or Datroway monotherapy versus current standard of care for MIUC (¥2900.0000, 0)
Nuvation Bio announces FDA Fast Track designation for safusidenib for treatment of IDH1-mutant glioma ($7.26, 0.00)
StreetAccount Summary - Trading higher/lower: Japan mid-day
Top-line results from DESTINY-Lung04 phase 3 trial of Daiichi Sankyo and AstraZeneca's Enhertu show statistically significant PFS for HER2 mutant NSCLC (¥2660.0000, 0)
China's NMPA approves Daiichi Sankyo and AstraZeneca's Enhertu to be combined with pertuzumab for first-line treatment of HER2 positive breast cancer (¥2805.0000, 0)
EU approves AstraZeneca and Daiichi Sankyo Datroway for First-Line Metastatic TNBC patients ineligible for immunotherapy (¥2567.5000, 0)
Transcript Intelligence: Daiichi Sankyo Q1 Earnings Guidance
Transcript Intelligence: Daiichi Sankyo Q1 Earnings Themes
Powered by FactSet Research Systems Inc.